These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 25131061)

  • 21. Hepatitis C virus treatment with pegylated interferon-alfa therapy leading to generalized interstitial granuloma annulare and review of the literature.
    Ahmad U; Li X; Sodeman T; Daboul I
    Am J Ther; 2013; 20(5):585-7. PubMed ID: 21317616
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pegylated interferon alfa-2a and ribavirin for recurrent hepatitis C after liver transplantation.
    Mukherjee S
    Transplant Proc; 2005 Dec; 37(10):4403-5. PubMed ID: 16387131
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospective controlled studies.
    Xirouchakis E; Triantos C; Manousou P; Sigalas A; Calvaruso V; Corbani A; Leandro G; Patch D; Burroughs A
    J Viral Hepat; 2008 Oct; 15(10):699-709. PubMed ID: 18673428
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pegylated interferon alpha-2a and ribavirin combination therapy in HCV liver transplant recipients. Experience of 7 cases.
    Iacob S; Gheorghe L; Hrehoret D; Becheanu G; Herlea V; Popescu I
    J Gastrointestin Liver Dis; 2008 Jun; 17(2):165-72. PubMed ID: 18568137
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapy with boceprevir or telaprevir in HIV/hepatitis C virus co-infected patients to treat recurrence of hepatitis C virus infection after liver transplantation.
    Antonini TM; Furlan V; Teicher E; Haim-Boukobza S; Sebagh M; Coilly A; Bonhomme-Faivre L; Roque-Afonso AM; Vittecoq D; Samuel D; Taburet AM; Duclos-Vallée JC
    AIDS; 2015 Jan; 29(1):53-8. PubMed ID: 25387314
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: an open-label series.
    Rodriguez-Luna H; Khatib A; Sharma P; De Petris G; Williams JW; Ortiz J; Hansen K; Mulligan D; Moss A; Douglas DD; Balan V; Rakela J; Vargas HE
    Transplantation; 2004 Jan; 77(2):190-4. PubMed ID: 14742979
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Telaprevir in treatment of recurrent hepatitis C infection in liver transplant recipients.
    Nair S; Waters B
    Exp Clin Transplant; 2014 Apr; 12(2):117-22. PubMed ID: 24702143
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The role and possibilities of natural interferon treatment in chronic hepatitis C: experience with natural interferon treatment for patients barred from combined antiviral therapy because of the STOP rule].
    Horváth G; Tolvaj G; Halász T; Stotz G
    Orv Hetil; 2007 Aug; 148(33):1545-50. PubMed ID: 17686672
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of pegylated interferon alfa-2a and ribavirin on hepatic fibrosis in liver transplant patients with recurrent hepatitis C: an open-label series.
    Mukherjee S; Lyden E
    Hepatogastroenterology; 2006; 53(70):561-5. PubMed ID: 16995462
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of simeprevir following pre-emptive pegylated interferon/ribavirin treatment for recurrent hepatitis C in living donor liver transplant recipients: a 12-week pilot study.
    Tanaka T; Sugawara Y; Akamatsu N; Kaneko J; Tamura S; Aoki T; Sakamoto Y; Hasegawa K; Kurosaki M; Izumi N; Kokudo N
    J Hepatobiliary Pancreat Sci; 2015 Feb; 22(2):144-50. PubMed ID: 25338946
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Catatonia associated with pegylated interferon-α 2b and ribavirin for hepatitis C.
    Quinn D; Kuchler E; Deming P; Arora S
    Psychosomatics; 2012; 53(4):400-1. PubMed ID: 22748752
    [No Abstract]   [Full Text] [Related]  

  • 32. Efficacy of interferon Beta combined with cyclosporine induction and intensified therapy for retreatment of chronic hepatitis C.
    Inoue K; Watanabe T; Yamada M; Yoshikumi H; Ogawa O; Yoshiba M
    Transplant Proc; 2009; 41(1):246-9. PubMed ID: 19249526
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of interferon based antiviral therapy for recurrent hepatitis C in patients who received steroid free immunosuppression for liver transplantation.
    Nair S; Lipscomb J; Eason J
    Transplantation; 2008 Aug; 86(3):418-22. PubMed ID: 18698245
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pegylated interferon alfa-2a and ribavirin treatment for recurrent hepatitis C: role of steatosis and body mass index.
    Testino G; Gentile R; Ansaldi F; Borro P; Ravetti G; Icardi G; Sumberaz A
    Panminerva Med; 2009 Jun; 51(2):135-6. PubMed ID: 19776716
    [No Abstract]   [Full Text] [Related]  

  • 35. Ribavirin with either standard or pegylated interferon to treat recurrent hepatitis C after liver transplantation.
    Cicinnati VR; Iacob S; Klein CG; Baba HA; Sotiropoulos GC; Hilgard P; Erim Y; Broelsch CE; Gerken G; Beckebaum S
    Aliment Pharmacol Ther; 2007 Jul; 26(2):291-303. PubMed ID: 17593075
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antiviral therapy of symptomatic HCV-mixed cryoglobulinemia after liver transplant: case report and literature review.
    Francesca Donato M; Banfi G; Cresseri D; Battista Fogazzi G; Martin P; Messa P; Fabrizi F
    Int J Artif Organs; 2013 May; 36(5):367-72. PubMed ID: 23446762
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Achievement of sustained viral response after switching treatment from pegylated interferon α-2b to α-2a and ribavirin in patients with recurrence of hepatitis C virus genotype 1 infection after liver transplantation: a case report.
    Kawaoka T; Hiraga N; Takahashi S; Takaki S; Tsuge M; Nagaoki Y; Hashimoto Y; Katamura Y; Miki D; Hiramatsu A; Waki K; Imamura M; Kawakami Y; Aikata H; Ochi H; Tashiro H; Ohdan H; Chayama K
    Intervirology; 2012; 55(4):306-10. PubMed ID: 21865660
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial.
    Liu CH; Huang CF; Liu CJ; Dai CY; Liang CC; Huang JF; Hung PH; Tsai HB; Tsai MK; Chen SI; Lin JW; Yang SS; Su TH; Yang HC; Chen PJ; Chen DS; Chuang WL; Yu ML; Kao JH
    Ann Intern Med; 2013 Dec; 159(11):729-38. PubMed ID: 24297189
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation.
    Fernández I; Meneu JC; Colina F; García I; Muñoz R; Castellano G; Fuertes A; Abradelo M; Lumbreras C; Moreno E; Solís-Herruzo JA
    Liver Transpl; 2006 Dec; 12(12):1805-12. PubMed ID: 17133585
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acute Graft Rejection and Formation of De Novo Donor-Specific Antibodies Triggered by Low Cyclosporine Levels and Interferon Therapy for Recurrent Hepatitis C Infection After Liver Transplantation: A Case Report.
    Nakano R; Ohira M; Ishiyama K; Ide K; Kobayashi T; Tahara H; Shimizu S; Arihiro K; Imamura M; Chayama K; Tanaka Y; Ohdan H
    Transplant Proc; 2017 Sep; 49(7):1634-1638. PubMed ID: 28838454
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.